[en] Applying the method proposed by R. Crespo and J. A. Tostevin to p-³He elastic scattering, the treatment of Coulomb interaction of momentum space is studied. The differential cross sections and spin observables at 500 and 300 MeV are calculated with R = 7 fm. The present results are compared with those given in V-P method. It shows that the applicable range of angular momentum and momentum transfer in R-J method are wider than those in V-P method

[en] Using a microscopic momentum space optical potential and the method for treating the Coulomb force, which is propose by R. Crespo and J.A.Tostevin, the authors calculated the differential cross section of elastic nucleon scattering from the ³H and ³He mirror nuclei at 500 MeV and the ratio of cross sections. The charge symmetry breaking effects due to the Coulomb force between the proton and nuclei are shown

[en] Lung cancer is the most common primary malignant tumor. Because most sufferers have already been in later stage in their first diagnosis, the lump body infringing upon the important organs often influences the excision of tumor. ¹²⁵I seeds permanent implantation is a new method for tumor brachytherapy, which contributes to kill the tumor completely, ensures the normal physiological functions of organs,reduces tissue injuries and treatment of complications, and raises the survival rate of sufferers. The rapid promotion of this technique is also followed by radiation risks in the treatment. Currently, the researches of ¹²⁵I seeds implantation is limited to the aspects of treatment means and effects, with no detailed study in intraoperative usage, disinfection and protection. Although a satisfactory curative effect is the key in the treatment,the studies in protection principles, means and technological upgradation are also too important to be ignored. (authors)

[en] Objective: To evaluate the efficacy of percutaneous interstitial implantation with ¹²⁵I seeds for recurrent patients of postoperative non-small cell lung carcinoma (NSCLC) guided by CT. Methods: Thirty-two NLCLC patients were verified by biopsy pathology. Prescribed dose was 90 Gy. The percutaneous interstitial implantation of ¹²⁵I seeds treatment was guided by CT. The carcinoma were scanned by CT and compared before and 6 months after treatment. Then judge the curative effect according to the curative standard put forward by World Health Organization. All the patients were followed-up for 6 to 72 months, mean 24 months. Results: The mean radioactive dose of therapy group was 153.7 Gy, D₉₀ was 93.5 Gy. Among the 32 follow-up cases, the complete and partial remission rate was 90.6%, and no major complications. One and two year survival rate were 87% and 73%, mean survival was 35 months. Conclusion: Percutaneous interstitial implantation with ¹²⁵I seeds for recurrent patients of postoperative NSCLC guided by CT is a valid, minimally invasive and efficient method. (authors)

[en] Objective: To investigate the feasibility, efficacy and complications of CT guided radioactive ¹²⁵I seed implantation in the treatment of lung cancer. Methods: According to the different treatment methods, 65 patients with lung cancer were divided into two groups, 37 cases in the implantation alone group received CT guided ¹²⁵I seeds interstitial implantation, the other 28 cases in the combination treatment group received interstitial ¹²⁵I seeds implantation combined with chemotherapy. All the patients were examined by posologic validation, and were followed up termly. Results: The total effective rate of 65 patients was 80.0%, 1-year survival rate was 90.8%. The effective rates of implantation alone group and combination treatment group were 67.6% and 96.4% respectively. There was a significant difference between the two groups (χ²=8.298, P<0.01). Before treatment, all the patients' mean diameter of the tumor was 5.48 cm; while it was 3.77 cm after treatment (t=7.764, P<0.01). Complications included pneumothorax (36 cases), bloody sputum (7 cases), fever (4 cases) which improved after treatment in 65 patients,but without radiation pneumonia. Conclusion: ¹²⁵I seed implantation is a highly effective treatment without severe complications in the treatment of lung cancer. (authors)

[en] Objective: To evaluate the technic, result and complications of interstitial implantation of ¹²⁵I seeds for NSCLC guided by CT aided with three dimensional treatment planning system (TPS). Methods: Fifty-three NLCLC patients confirmed by puncture pathology were treatment with interstitial implantation of ¹²⁵I seeds guided by CT with TPS monitored immediately by CT after implantation. Another scanning of the tumor was repeated after 2 months. Results: The mean radioactive dose were 150.5 Gy, mPD 84.6 Gy, D₉₀92.4 Gy, D₉₀ > mPD. Of 37 rescanned patients, 10 showed CR while 27 showed PR. Complications were pneumothorax 19, hemoptysis 7, fever 5, dislodge 4 and seeds moved 2. Conclusion: CT guided transcutaneous interstitial implantation of ¹²⁵I seeds is valid and only minimally traumatic for NLCLC. (authors)

[en] Objective: To evaluate the clinical effects of CT-guided ¹²⁵I radioactive seed implantation in treatment of stage Ⅲ non-small cell lung cancer (NSCLC) and the influential factors of prognosis. Methods: 247 patients of stage Ⅲa/Ⅲb NSCLC underwent CT-guided ¹²⁵I radioactive seed implantation. The clinical effects and the factors affecting prognosis were analyzed by univariate and multivariate analyses. Results: The 1-, 3-, and 5- year overall survival rates were 82.8%, 23.8%, and 11.5 %, respectively. The median survival time was 24.8 months, and the local control rate was 92.2 %, 63.8%, and 25.7%, respectively. The 5- year overall survival rate was 14.7%, and the median survival time was 29.7 months of the stage Ⅲ, patients. And the 5- year overall survival rate was 11.2%, and the median survival time was 24.0 months at the stage Ⅲb. Univariate analysis showed that age, course of disease, hemoglobin before treatment, clinical stage, maximum diameter of tumor, prescribed dose (PD), post-operational mean dose,post-operational dose covering 100% volume (D₁₀₀), remedial model were the main prognostic factors; however, multivariate analysis revealed that hemoglobin ≥ 120 g/L before treatment, post-operational dose covering 100% volume (D₁₀₀) and maximum diameter of tumor were the independent risk factors for predicting the survival. Aerothorax was observed in 37 patients with an incidence rate of 14.9%, and hemothorax was observed in 22 patients with an incidence rate of 9%. Conclusions: ¹²⁵I radioactive seed implantation therapy is effective in the treatment of stage Ⅲ NSCLC. Hemoglobin level before treatment, post-operational dose covering 100% volume (D₁₀₀), and maximum diameter of tumor are the main prognostic factors for the NSCLC patients treated with radiotherapy for NSCLC. (authors)

[en] Objective: To observe the changes of the ultrastructure of dorsal root ganglion (DRG) and the behaviors of hind limb after implantation of radioactive ¹²⁵I seeds around the DRG in rats. Methods: 36 adult male Sprague-Dawley rats were randomly divided into three groups with different radioactivity ¹²⁵I seeds implanted around DRG, named control group (no irradiation, n = 12), low radioactivity group (14.8 MBq, n = 12) and high radioactivity group (29.6 MBq, n = 12). The paw withdrawal threshold and combined behavior score were observed 24 h prior to seed implantation and at 48, 168, 336, 720 and 1440 h after the treatment. Two rats were killed at 336 h and 1440 h to observe the ultrastructure of L₅ DRG. Results: Compared to the control without operation, PWT of the high radioactivity group were significantly higher than that of other groups (t = 2.972, P < 0.05). The in most of DRG low radioactivity group at 336 h were normal with a few abnormal cells. The DRG at 1440 h in low radioactivity group and in at 336 h high radioactivity group showed nuclear membrane buckling, nucleolus-set, mitochondrial swelling, lysosome increase, endoplasmic reticulum dilation and vacuolization. At 1440 h in the high radioactivity group, most of nuclear membrane invaginated, part of nuclear membrane obscured and mitochondrial swelled, but nuclear pyknosis and apoptotic body were not observed. Conclusions DRG can be injured after implantation of radioactive ¹²⁵I around DRG, and the threshold of mechanical pain would be elevated after implanting radioactive ¹²⁵I seeds. (authors)

[en] Objective: To evaluate the clinical outcomes and the prognostic factors in patients with pulmonary metastases treated with CT-guided radioactive ¹²⁵I seed implantation (CTRISI). Methods: A total of 50 patients were treated with implantation of ¹²⁵I radioactive seeds under computed tomography (CT) guidance or combined with surgical resection. There were 10 (20%) patients with colorectal cancer, 8 (16%) patients with malignant fibrous histiocytoma, 5 (10%) patients with sarcoma, 22 (44%) patients with other cancer, respectively. CTRISI was the only treatment in 45 patients (90%) and combined with surgical resection in 5 (10%). The local control rate, the survival rate and the factor associated with overall survival were evaluated. Results: The D_90% was (112.3±12.2) Gy, the V₉₀ was 91.3%±8.2%, and the postoperative matched peripheral dose (MPD) was 106.2 Gy. The local control rate for 1-, 2-, 3-, 4-, 5-year were 95.8%, 86.5%, 56.6%, 42.4%, 31.1%, respectively. At a mean follow-up of 26 months (7-74 months), 6 patients were alive. The median survival time was 27.1 months. The survival rate for 1-, 2-, 3-, 4-, 5-year were 83.4%, 52.3%, 38.7%, 20.3%, 13.7%, respectively. Lesion size ≤4 cm or >4 cm was an important prognostic factor associated with overall survival(χ² = 4.621, P < 0.05) and disease-free survival(χ² = 7.548, P < 0.05). Conclusions: CTRISI is safe in these patients with pulmonary metastases, with promising results. Surgical resection remains the standard for resectable patients, while CTRISI alone or combined with surgery might offer an alternative in selected patients. (authors)

[en] Objective: To explore the quality control and the short-term curative efficacy of ¹²⁵I radioactive seeds implantation in the treatment of spinal metastases by using co-planar template(CPT) assisted CT guidance. Method: Totally 12 cases of primary tumor were diagnosed by pathology, imaging changes for 16 lesions were consistent with the characteristics of spinal metastatic tumor. The prescription dose (PD) was 80 Gy, seed activity was 1.48 × 10⁷ - 2.59 × 10⁷ Bq(0.4 - 0.7 mCi). According to preoperative plan, spinal metastases were treated with CPT assisted CT guided ¹²⁵I radioactive seeds implantation. The distribution of seeds was observed immediately after operation and the dose was assessed. Patients were followed up by CT to determine the change of tumor diameter and evaluate the efficacy. Follow-up time ranged from 3 to 29 months. And the improvement of pain was evaluated by pain grading. Results: All of the 16 spinal metastases lesions were successfully implanted by the preoperative planning. After the implantation, quality verification showed the average dose of target region was (209.21 ± 37.16)Gy, D₉₀(115.29 ± 7.87)Gy, D₁₀₀(76.59 ± 5.53)Gy, V₉₀(99.30 ± 0.51)%, V₁₀₀(98.06 ± 1.15)%, conformal index (CI) 0.981 ± 0.012, external index (EI) 0.012 ± 0.007. And the average dose of the spinal cord was (30.47 ± 4.83)Gy. There was no significant difference in the mean dose between the target area and the spinal cord and the preoperative plan (P > 0.05). 3 months after surgery, among 16 spinal metastases lesions, complete response (CR) was 18.8% (3/16), PR (partial response) rate 62.5% (10/16), PD(progressive disease) rate 6.25%(1/16), SD(stable disease) rate 6.25%(1/16), effective rate (CR + PR) 81.3%. The were 3 cases in pain complete remission, 7 cases in partial remission, 2 cases in mild remission. The survival time range from 11 to 39 months. The median survival time was 24 months. No radiation damage of spinal cord was found. Conclusions: CT guided CPT can be used to control the position and radiation dose of the seeds implantation before the operation, so as to achieve the objective of treating tumor with fewer complications and improvement of patients' tolerance. (authors)